Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

neutralizing monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (2) Arenavirus (1) ATGL (1) Bacterial (3) c-Fms (2) c-Met/HGFR (2) Cadherin (1) Caspase (2) CCR (1) CMV (2) Complement System (1) CXCR (1) Drug Derivative (1) EGFR (3) ERK (1) Fc Receptor (FcR) (1) HBV (3) HIV (2) IFNAR (2) Influenza Virus (4) Interleukin Related (14) Melanocortin Receptor (1) Myosin (1) NF-κB (1) PARP (1) PCSK9 (1) RABV (2) RSV (2) SARS-CoV (8) STAT (1) Survivin (1) Tau Protein (3) TGF-beta/Smad (1) TGF-β Receptor (1) Thrombin (1) TNF Receptor (3) Transmembrane Glycoprotein (1) Tyrosinase (1) β-catenin (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (4) Infection (27) Inflammation/Immunology (28) Metabolic Disease (6) Neurological Disease (6)

By Targets:

Akt (1)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (1)

Apoptosis (2)

Arenavirus (1)

ATGL (1)

Bacterial (3)

c-Fms (2)

c-Met/HGFR (2)

Cadherin (1)

Caspase (2)

CCR (1)

CMV (2)

Complement System (1)

CXCR (1)

Drug Derivative (1)

EGFR (3)

ERK (1)

Fc Receptor (FcR) (1)

HBV (3)

HIV (2)

IFNAR (2)

Influenza Virus (4)

Interleukin Related (14)

Melanocortin Receptor (1)

Myosin (1)

NF-κB (1)

PARP (1)

PCSK9 (1)

RABV (2)

RSV (2)

SARS-CoV (8)

STAT (1)

Survivin (1)

Tau Protein (3)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Thrombin (1)

TNF Receptor (3)

Transmembrane Glycoprotein (1)

Tyrosinase (1)

β-catenin (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (4)

Infection (27)

Inflammation/Immunology (28)

Metabolic Disease (6)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108810

Canakinumab Ilaris; ACZ 885	Interleukin Related	Inflammation/Immunology Cancer
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99756

Nirsevimab 2 Publications Verification MEDI8897	RSV	Infection
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC₅₀ values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

HY-P990876

Afimkibart PF-06480605; RVT-3101	TNF Receptor NF-κB IFNAR	Inflammation/Immunology
Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P9924

Ixekizumab LY2439821	Interleukin Related	Inflammation/Immunology
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (K_D<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .

HY-P9945

Mepolizumab SB 240563	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P9945A

Mepolizumab (anti-IL5)	Interleukin Related	Inflammation/Immunology
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P99111

Golimumab CNTO-148	TNF Receptor Apoptosis Interleukin Related Caspase	Inflammation/Immunology Cancer
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .

HY-P9964

Necitumumab 11F8; IMC-11F8; LY3012211	EGFR	Cancer
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .

HY-P990591

GSK-1070806 Aletekitug	Interleukin Related	Inflammation/Immunology
GSK-1070806 (Aletekitug) is a humanized IgG1/κ monoclonal antibody targeting IL-18. GSK-1070806 neutralizes IL-18 activity.GSK-1070806 can be used for the research of inflammation. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99340

Sotrovimab 4 Publications Verification VIR 7831; GSK-4182136	SARS-CoV	Infection Cancer
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .

HY-P9953

Certolizumab pegol 2 Publications Verification Certolizumab; CDP870	TNF Receptor	Inflammation/Immunology Cancer
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .

HY-P99583

Suvratoxumab MEDI4893	Bacterial	Infection Inflammation/Immunology
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .

HY-P99305

Metelimumab 3 Publications Verification CAT-192; Anti-TGFB1 Recombinant antibody	TGF-β Receptor	Inflammation/Immunology
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .

HY-P990036

Dazukibart PF-06823859	IFNAR	Inflammation/Immunology
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .

HY-P99053

Tralokinumab 2 Publications Verification CAT354	Interleukin Related Apoptosis Caspase Cadherin	Inflammation/Immunology
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .

HY-P99375

Narnatumab IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference antibody (narnatumab)	Tyrosinase c-Met/HGFR	Cancer
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a K_d of 32 pM. Narnatumab can be used for the research of cancer .

HY-P99424

Afasevikumab RG 7624; RO 5553110; NI-1401	Interleukin Related	Inflammation/Immunology
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .

HY-P99556

Tixagevimab AZD8895; COV2-2196	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-P99368

Lacnotuzumab MCS110	c-Fms	Metabolic Disease Cancer
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .

HY-P991069

VRC-01	HIV	Infection
VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection .

HY-P991363

AX-202	Myosin STAT	Inflammation/Immunology
AX-202 is a humanized IgG4 monoclonal antibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .

HY-P99750

Navivumab CT-P23	Influenza Virus	Infection
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .

HY-P9949

Reslizumab Sch 55700; CDP-835; JES1-39D10	Interleukin Related	Inflammation/Immunology
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with K_D values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .

HY-P990015

Tobevibart VIR-3434	HBV	Infection
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .

HY-P991446

MEDI-8852	Influenza Virus	Infection
MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991224

CAP-100	CCR	Inflammation/Immunology Cancer
CAP-100 is a **monoclonal antibody that targets CCR7*. CAP-100 neutralizes* the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .

HY-P99906

Sirexatamab DKN-01; LY-2812176	β-catenin	Cancer
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .

HY-P99900

Sevirumab MSL-109	CMV	Infection
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC₅₀ of 0.3 μg/mL .

HY-P99648

Gosuranemab BMS-986168; IPN007; BIIB092	Tau Protein	Neurological Disease
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .

HY-P990937

Pacibekitug PF-04236921; TOUR-006	Interleukin Related	Inflammation/Immunology
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) ^[1][2].

HY-P99342

Imdevimab 1 Publications Verification REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .

HY-P99395

Talacotuzumab 1 Publications Verification JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, *CD123*-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P99404

Quetmolimab E6011	CXCR	Inflammation/Immunology Cancer
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .

HY-P99347

Etesevimab CB 6; JS016	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .

HY-P99703

Libivirumab 17.1.41	HBV	Infection
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC₅₀s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .

HY-P99811

Rafivirumab CR57	RABV	Infection
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .

HY-P990071

Fepixnebart LY-3016859	EGFR	Neurological Disease Metabolic Disease Inflammation/Immunology
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .

HY-P99620

Firivumab CT-P22; CT120	Influenza Virus	Infection
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-P99792

Ormutivimab NM57; rhRIG	RABV	Infection
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic Bacterial	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .

HY-108739

Idarucizumab BI 655075	Thrombin	Cardiovascular Disease
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .

HY-P991221

ALD1613	Melanocortin Receptor	Metabolic Disease
ALD1613 is a potent neutralizing monoclonal antibody against adrenocorticotropic hormone (ACTH). ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels .

HY-P991574

MEDI-5884 REG-101	ATGL	Cardiovascular Disease
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .

HY-P99307

Namilumab AMG-203; Anti-Human CSF2 Recombinant antibody	c-Fms	Inflammation/Immunology
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .

Cat. No.	Product Name	Target	Research Area

HY-P4025

ELDKWA	HIV	Others
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .

Cat. No.	Product Name	Target	Research Area	Image